Page 93 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer

Initial clinical trials with 89Zr-immuno-PET in oncology
REFERENCES
1. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117-4126.
2. Peeters M, Karthaus M, Rivera F, Terwey J-H, Douillard J-Y. Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status. Drugs. 2015;75:731-748.
3. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013;341:1192-1198.
4. Evans JB, Syed BA. From the analyst’s couch: Next-generation antibodies. Nat Rev Drug Discov.
2014;13:413-414.
5. Reichert JM. Antibodies to watch in 2016. MAbs. 2016;8:197-204.
6. Van Dongen GA, Huisman MC, Boellaard R, et al. 89Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied? Q J Nucl Med Mol Imaging. 2015;59:18-38.
7. Verel I, Visser GWM, Boellaard R, Walsum MS, Snow GB, Dongen GAMS van. 89Zr Immuno-PET: 4 Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies. J Nucl Med. 2003;44:1271-1281.
8. Vosjan MJWD, Perk LR, Visser GWM, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl- desferrioxamine. Nat Protoc. 2010;5:739-743.
9. Perk LR, Vosjan MJWD, Visser GWM, et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno- PET imaging. Eur J Nucl Med Mol Imaging. 2010;37:250-259.
10. Makris NE, Boellaard R, Visser EP, et al. Multicenter harmonization of 89Zr PET/CT performance. J Nucl Med. 2014;55:264-267.
11. Börjesson PKE, Jauw YWS, Boellaard R, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133-2140.
12. Börjesson PKE, Jauw YWS, de Bree R, et al. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50:1828- 1836.
13. Tijink BM, Buter J, de Bree R, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006;12:6064-6072.
14. Bree R de, Roos JC, Quak JJ, Hollander W den, Snow GB, Dongen GA van. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res. 1995;1:591-598.
15. Colnot DR, Quak JJ, Roos JC, et al. Phase I Therapy Study of 186Re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck. J Nucl Med. 2000;41:1999-2010.
16. Stroomer JW, Roos JC, Sproll M, et al. Safety and biodistribution of 99mTechnetium-labeled anti- CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res. 2000;6:3046- 3055.
17. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012:CD006243.
18. Gong J, Liu T, Fan Q, et al. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer. 2016;16:68.
19. Leone F, Perissinotto E, Cavalloni G, et al. Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. J Leukoc Biol. 2003;74:593-601.
20. Tsé C, Gauchez A-S, Jacot W, Lamy P-J. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev. 2012;38:133-142.
91